Vanguard Global Advisers
BDTX icon

Vanguard Global Advisers’s Black Diamond Therapeutics BDTX Stock Holding History

Vanguard Global Advisers’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29K Hold
15,667
– – ﹤0.01% 3234
2026
Q1 		$33.4K Buy
+15,667
New +$37.3K ﹤0.01% 3169

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Vanguard Global Advisers's BDTX Position: Q2 2026 in Review

Vanguard Global Advisers held its Black Diamond Therapeutics (BDTX) position steady in Q2 2026 at 15,667 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #3234.

Vanguard Global Advisers first reported a position in BDTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $33.4K in Q1 2026. 94 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Vanguard Global Advisers held 15,667 shares of Black Diamond Therapeutics worth $29K as of Q2 2026.
  • Vanguard Global Advisers left its Black Diamond Therapeutics share count unchanged in Q2 2026.
  • Black Diamond Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3234 holding.
  • Vanguard Global Advisers first reported a position in Black Diamond Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Black Diamond Therapeutics position peaked at $33.4K in Q1 2026.
  • 94 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.